Endo International plc

293 articles about Endo International plc

• Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®

  6/5/2023

  Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) in treating men with Peyronie's disease (PD) were published by peer-reviewed journal Urology ®.

• Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials

  5/24/2023

  Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial in the U.S. Endo will commercialize the FDA-approved product through its Par Sterile Products business and expects to begin shipping in summer 2023.

• ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

  5/8/2023

  Endo International plc (OTC: ENDPQ) today reported financial results for the first-quarter ended March 31, 2023.

• Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection)

  4/26/2023

  Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively "Endo") have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo ™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S.

• Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

  4/17/2023

  Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping argatroban injection to healthcare providers through Premier's Premier ProRx ® private-label program, a guaranteed supply for hospitals and health systems.

• Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

  4/3/2023

  Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.

• Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

  3/13/2023

  Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis.

• Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules

  3/10/2023

   Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Allergan's Pylera.

• ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS

  3/6/2023

  Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2022.

• Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)

  12/6/2022

  Endo International plc (OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

• Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool

  10/27/2022

  Endo International plc (OTC: ENDPQ) and the Sexual Medicine Society of North America (SMSNA) announced today the launch of a Peyronie's Self-Assessment application, available now in the App Store and Google Play.

• Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting

  10/7/2022

  Endo International plc (OTC: ENDPQ) announced today that data from studies of Endo Aesthetics' Qwo ® (collagenase clostridium histolyticum-aaes), an FDA-approved injectable for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during the American Society for Dermatologic Surgery annual meeting.

• Endo Launches Unscripted Video Series With Real Dupuytren's Contracture Patients

  10/5/2022

  Endo International plc announced the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren's contracture, a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans.

• 

  Endo Files for Bankruptcy in Wake of Opioid Lawsuits and Mounting Debt - Updated

  8/18/2022

  Endo International filed for bankruptcy Tuesday in the U.S. Bankruptcy Court in New York due to its debt load of over $8 billion and the thousands of opioid lawsuits.

• Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

  8/17/2022

  Endo International plc announced that it has entered into a restructuring support agreement with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebtedness, address remaining opioid and other litigation-related claims, and best position Endo for the future.

• ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

  8/9/2022

  Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022.

• Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

  7/15/2022

  Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada.

• Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor

  7/1/2022

  Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial.

• Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder

  7/1/2022

  Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or "CCH") in participants with adhesive capsulitis (AC) of the shoulder, commonly known as "frozen shoulder."

• Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain

  6/13/2022

  Endo International plc announced that its subsidiary Endo Ventures Limited has executed an agreement with Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product.